Clinical Peptide Medicine — Structured. Applied. Evolving.
PE-22-28 Peptide Guide: TREK-1, Spadin, Depression, Neurogenesis, Mood Signaling, and More.
PE-22-28 is a seven-amino-acid peptide derived from spadin, an endogenous peptide associated with the sortilin/pro-neurotensin receptor-3 system, and developed as a potent inhibitor of the TREK-1 potassium channel.
Its sequence is:
- GLY — VAL — SER — TRP — GLY — LEU — ARG
or:
- GVSWGLR.
PE-22-28 is interesting because it represents a very different approach to mood biology.
Most people think about depression through:
- SEROTONIN
- NOREPINEPHRINE
or:
- DOPAMINE.
PE-22-28 points toward another layer:
- ION-CHANNEL REGULATION OF NEURONAL EXCITABILITY.
Its principal research target is:
- TREK-1
also known as:
- K2P2.1
or:
- KCNK2.
TREK-1 is a:
- TWO-PORE-DOMAIN POTASSIUM CHANNEL.
That may sound like a small technical detail.
- It is not.
Potassium channels help determine:
- resting membrane potential
- neuronal excitability
- response threshold
- firing behavior
- network stability
- responses to mechanical, thermal, lipid, and stress signals
So the best way to understand PE-22-28 is not simply:
- “AN ANTIDEPRESSANT PEPTIDE.”
That is too far downstream.
A better description is:
- A SPADIN-DERIVED NEUROACTIVE PEPTIDE DESIGNED TO INHIBIT TREK-1 AND THEREBY MODIFY THE ELECTRICAL AND PLASTICITY ENVIRONMENT OF NEURAL CIRCUITS ASSOCIATED WITH MOOD AND STRESS ADAPTATION.
That is a much more useful model.
PE-22-28 has shown very high affinity for TREK-1 in experimental systems, with reported IC50 values around 0.12 nM, considerably stronger than the parent peptide spadin in the same experimental framework.
THE CORE MECHANISM MAP
SORTILIN PROPEPTIDE
↓
SPADIN
↓
Shortened analog:
- PE-22-28 — GVSWGLR
↓
TREK-1 INHIBITION
↓
BACKGROUND K+ CURRENT ↓
↓
Potential alteration in:
- NEURONAL EXCITABILITY
↓
Potential:
- NEUROGENESIS
- SYNAPTIC / NETWORK PLASTICITY
- MOOD-CIRCUIT ADAPTATION
↓
Potential:
- ANTIDEPRESSANT-LIKE EFFECT
The core idea is:
- PE-22-28 TARGETS THE ELECTRICAL GATING ENVIRONMENT OF NEURAL CIRCUITS RATHER THAN DIRECTLY TARGETING A CLASSIC MONOAMINE TRANSPORTER.
WHAT THIS MECHANISM MAY SUGGEST
Mechanistically, PE-22-28 deserves research interest in:
- depression
- treatment-resistant mood disorders
- stress-related neural dysfunction
- impaired neuroplasticity
- mood disorders where monoamine-directed strategies are insufficient
- neurogenesis research
- TREK-1-related neurobiology
- novel rapid-acting antidepressant development
Its strongest conceptual niche may be:
- DEPRESSION AS A NETWORK-PLASTICITY DISORDER RATHER THAN SIMPLY A MONOAMINE DEFICIENCY.
WHAT THIS MECHANISM DOES NOT PROVE
PE-22-28 biology does not prove that it:
- treats human depression
- works faster than SSRIs in humans
- treats bipolar depression
- prevents suicide
- treats anxiety simply because neuronal excitability is involved
- treats ADHD
- permanently increases neurogenesis
- is appropriate whenever someone has low mood
- replaces psychotherapy
- replaces evaluation of medical causes of depressive symptoms
Again:
- DEPRESSION IS A SYNDROME.
The causes may include:
- major depressive disorder
- bipolar disorder
- thyroid disease
- anemia
- medication effects
- substance use
- sleep apnea
- chronic inflammation
- trauma
- neurodegenerative disease
- grief
- chronic pain
Same symptom.
Different:
- BIOLOGY.
PRECLINICAL EVIDENCE
PE-22-28 is a heptapeptide composed of 7 amino acids, specifically following the sequence GVSWGLR. This compound was developed from spadin, a peptide that originates from the sortilin propeptide. Preclinical research has shown that the original spadin molecule exhibited antidepressant-like effects, but it had relatively short in-vivo activity. Consequently, researchers focused on its blood-degradation products to create shorter analogs that maintain the desired effects. One of the most promising outcomes of this research was PE-22-28. The elegant rationale behind its design was to preserve the ability to block the TREK-1 potassium channel, thus enhancing neurogenesis while also improving affinity, stability, and pharmacological usefulness.
HUMAN CLINICAL EVIDENCE
SORTILIN PROPEPTIDE
↓
Processing
↓
SPADIN
↓
Shortened active sequence
↓
PE-22-28 — GVSWGLR
↓
TREK-1 POTASSIUM CHANNEL INHIBITION
↓
Potential effects on:
NEURONAL EXCITABILITY
NEUROPLASTICITY
NEUROGENESIS
MOOD-RELATED CIRCUITS
↓
Potential:
ANTIDEPRESSANT-LIKE ACTIVITY
Again:
PE-22-28 is not simply:
A SHORTER SPADIN.
It was selected because this shorter sequence retains — and in some assays strengthens — the desired:
TREK-1 POTASSIUM CHANNEL INHIBITORY PHARMACOLOGY.
DO NOT BEGIN WITH PE-22-28
Begin with: WHAT IS ACTUALLY DRIVING THE MOOD DISORDER?
Then:
PHYSIOLOGY
↓
PATTERN
↓
MECHANISM
↓
EVIDENCE
↓
RISK
↓
MONITORING
↓
DECISION
PHYSIOLOGY
Healthy mood regulation depends on:
- neurotransmission
- neuronal excitability
- sleep
- HPA-axis signaling
- reward circuitry
- neuroplasticity
- inflammation
- mitochondrial function
- psychosocial environment
PE-22-28 appears most relevant to:
- EXCITABILITY + PLASTICITY.
Again
that is:
- ONE PART OF THE NETWORK.
EVIDENCE
Ask:
WHAT EVIDENCE ACTUALLY EXISTS FOR PE-22-28?
Not:
- spadin generally.
Not:
- TREK-1 knockout mice generally.
Not:
- all antidepressants.
Specifically:
PE-22-28.
At present, the strongest direct evidence is:
- IN-VITRO + ANIMAL.
That does not negate the mechanism.
It tells us where:
- THE TRANSLATION CURRENTLY STANDS.
PATTERN
What is actually present?
- major depressive disorder?
- bipolar depression?
- adjustment disorder?
- trauma-related depression?
- inflammatory depression?
- medication-related mood change?
- sleep-related mood dysfunction?
- endocrine disorder?
Again:
- “DEPRESSED” IS NOT A MOLECULAR DIAGNOSIS.
RISK
Potential theoretical and practical considerations include:
- altering neuronal excitability in unintended circuits
- mood destabilization in susceptible individuals
- unknown human dose-response
- unknown long-term channel adaptation
- interaction with psychiatric medications
- product-quality uncertainty
- using a research peptide instead of appropriately evaluating suicidality, bipolarity, substance use, or medical causes of depression
Because human therapeutic characterization remains early:
- UNKNOWN DOES NOT MEAN DANGEROUS.
But it also does not mean:
- KNOWN SAFE.
The appropriate response is:
- CALIBRATED UNCERTAINTY.
MECHANISM
Does TREK-1 biology match:
- THE DOMINANT BOTTLENECK?
If low mood is caused primarily by:
- UNTREATED HYPOTHYROIDISM,
correct:
- THYROID PHYSIOLOGY.
If the patient has:
- BIPOLAR DISORDER,
the treatment framework is fundamentally different from:
- UNIPOLAR DEPRESSION.
If severe sleep deprivation is driving:
- MOOD + COGNITION,
restore:
- SLEEP.
But if the dominant pattern involves:
- MALADAPTIVE MOOD NETWORKS + IMPAIRED PLASTICITY,
TREK-1 becomes:
- A MUCH MORE INTERESTING TARGET.
MONITORING
Monitoring should follow:
- THE MOOD PHENOTYPE + THE NEURAL HYPOTHESIS.
MOOD
- depressive symptom burden
- anhedonia
- motivation
- functional impairment
- validated scales when useful
COGNITION
- attention
- processing
- executive function
- mental fatigue
SLEEP
- sleep duration
- sleep initiation
- early waking
- circadian pattern
SAFETY / MOOD STABILITY
- agitation
- unusual activation
- mood cycling
- impulsivity
- worsening anxiety
- suicidality
Again
if the hypothesis is:
- BETTER MOOD-NETWORK ADAPTATION,
then:
- FUNCTION SHOULD IMPROVE.
Not merely:
- THE PATIENT SHOULD FEEL STIMULATED.
THE PRAXIS 5
MECHANISM
PE-22-28 is a heptapeptide composed of 7 amino acids, specifically following the sequence GVSWGLR. This compound was developed from spadin, a peptide that originates from the sortilin propeptide. Preclinical research has shown that the original spadin molecule exhibited antidepressant-like effects, but it had relatively short in-vivo activity. Consequently, researchers focused on its blood-degradation products to create shorter analogs that maintain the desired effects. One of the most promising outcomes of this research was PE-22-28. The elegant rationale behind its design was to preserve the ability to block the TREK-1 potassium channel, thus enhancing neurogenesis while also improving affinity, stability, and pharmacological usefulness.
EVIDENCE
SORTILIN PROPEPTIDE
↓
Processing
↓
SPADIN
↓
Shortened active sequence
↓
PE-22-28 — GVSWGLR
↓
TREK-1 POTASSIUM CHANNEL INHIBITION
↓
Potential effects on:
NEURONAL EXCITABILITY
NEUROPLASTICITY
NEUROGENESIS
MOOD-RELATED CIRCUITS
↓
Potential:
ANTIDEPRESSANT-LIKE ACTIVITY
Again:
PE-22-28 is not simply:
A SHORTER SPADIN.
It was selected because this shorter sequence retains — and in some assays strengthens — the desired:
TREK-1 POTASSIUM CHANNEL INHIBITORY PHARMACOLOGY.
RISK
TREK-1, which stands for TWIK-RELATED POTASSIUM CHANNEL-1, is encoded by the KCNK2 gene. This important TREK-1 potassium channel is part of the TWO-PORE-DOMAIN POTASSIUM CHANNEL — K2P family. These channels play a significant role in contributing to the BACKGROUND POTASSIUM CURRENT, which is essential for establishing the resting electrical state of a neuron. As such, TREK-1 is vital in neurogenesis, influencing how easy or difficult it is for a neuron to fire, particularly in various physiological contexts, including the application of peptides like PE-22-28.
MONITORING
Neurons maintain a negative resting membrane potential partly because: K+ LEAVES THE CELL. TREK-1 potassium channel contributes to this: POTASSIUM LEAK CURRENT. In simplified form: TREK-1 OPEN ↓ K+ efflux ↓ Membrane becomes relatively more: HYPERPOLARIZED ↓ Neuron becomes: LESS EXCITABLE PE-22-28 ↓ TREK-1 INHIBITION ↓ Background K+ current decreases Potential: NEURONAL EXCITABILITY ↑. Again, that does not mean: “MORE EXCITABILITY = BETTER MOOD.” The real biology depends on: WHICH CIRCUIT and: WHICH STATE THE NETWORK IS IN, particularly in the context of neurogenesis.
PATIENT CONTEXT
TREK-1 became particularly interesting because: TREK-1-deficient animal models displayed behavioral phenotypes resembling: antidepressant exposure. This suggested that TREK-1 activity may participate in mood-regulatory circuits, potentially linking to neurogenesis. Spadin was then identified as an endogenous peptide capable of inhibiting the TREK-1 potassium channel. This discovery created an entirely different antidepressant strategy that does not increase serotonin directly but instead aims to change the electrical responsiveness of the neural network. PE-22-28 is an optimized descendant of that strategy.
SEVEN QUESTIONS TO ASK BEFORE PE-22-28
1. WHAT MOOD OR COGNITIVE PROBLEM ARE WE ACTUALLY TRYING TO CHANGE?
depression?
anhedonia?
cognitive rigidity?
stress-related dysfunction?
something else?
2. WHAT IS DRIVING THAT PATTERN?
endocrine?
sleep?
medication?
trauma?
bipolarity?
inflammation?
network dysfunction?
3. DOES TREK-1 POTASSIUM CHANNEL / EXCITABILITY BIOLOGY MATCH THE BOTTLENECK?
That is the key mechanistic question.
4. WHAT TYPE OF EVIDENCE EXISTS FOR PE-22-28 ITSELF?
TREK-1 assay?
animal behavior?
neurogenesis?
human clinical evidence?
5. COULD ALTERING NEURONAL EXCITABILITY CREATE A DIFFERENT PROBLEM?
Especially:
activation?
anxiety?
agitation?
mood cycling?
6. WHAT WILL WE MONITOR?
depression?
anhedonia?
cognition?
sleep?
activation?
function?
7. WHAT WOULD DEFINE SUCCESS?
Not:
"THE BRAIN FELT MORE ACTIVE."
But:
MOOD, MOTIVATION, FUNCTION, AND ADAPTIVE CAPACITY IMPROVED WITHOUT DESTABILIZING THE NETWORK.
PE-22-28
KEY TAKEAWAYS
1. WHAT MOOD OR COGNITIVE PROBLEM ARE WE ACTUALLY TRYING TO CHANGE?
depression?
anhedonia?
cognitive rigidity?
stress-related dysfunction?
something else?
2. WHAT IS DRIVING THAT PATTERN?
endocrine?
sleep?
medication?
trauma?
bipolarity?
inflammation?
network dysfunction?
3. DOES TREK-1 POTASSIUM CHANNEL / EXCITABILITY BIOLOGY MATCH THE BOTTLENECK?
That is the key mechanistic question.
4. WHAT TYPE OF EVIDENCE EXISTS FOR PE-22-28 ITSELF?
TREK-1 assay?
animal behavior?
neurogenesis?
human clinical evidence?
5. COULD ALTERING NEURONAL EXCITABILITY CREATE A DIFFERENT PROBLEM?
Especially:
activation?
anxiety?
agitation?
mood cycling?
6. WHAT WILL WE MONITOR?
depression?
anhedonia?
cognition?
sleep?
activation?
function?
7. WHAT WOULD DEFINE SUCCESS?
Not:
"THE BRAIN FELT MORE ACTIVE."
But:
MOOD, MOTIVATION, FUNCTION, AND ADAPTIVE CAPACITY IMPROVED WITHOUT DESTABILIZING THE NETWORK.
THE BOTTOM LINE
PE-22-28 may be one of the most conceptually interesting peptides in the brain section because it shifts the entire conversation about mood.
The usual story is:
DEPRESSION
↓
SEROTONIN
↓
ANTIDEPRESSANT
But neurons do not function simply because neurotransmitters exist.
They function because:
- THE MEMBRANE IS ELECTRICALLY RESPONSIVE.
Before serotonin.
Before dopamine.
Before norepinephrine.
There is:
- MEMBRANE POTENTIAL.
There are:
- ION CHANNELS.
And one of those channels is:
- TREK-1.
So PE-22-28 gives us a different model:
TREK-1
↓
Controls part of background K+ current
↓
Shapes:
NEURONAL EXCITABILITY
PE-22-28
↓
TREK-1 INHIBITION
↓
Electrical responsiveness changes
↓
Potential:
NEUROPLASTICITY
NEUROGENESIS
↓
Potential:
MOOD-NETWORK ADAPTATION
That means the deeper question is not:
- “HOW MUCH SEROTONIN DOES THIS PATIENT HAVE?”
It may be:
- “HOW RESPONSIVE IS THE NETWORK TO THE SIGNALS IT ALREADY HAS?”
That is a very different model of psychiatric pharmacology.
But we also have to keep the translation honest.
The target is compelling.
The peptide is potent in experimental systems.
The animal antidepressant-like data are interesting.
The neurogenesis signal is interesting.
But the next major question remains:
- WHAT HAPPENS IN HUMANS?
That is where the field has to go.
And the Praxis question becomes:
- “WHAT is the actual depressive phenotype, what biological system is failing, is TREK-1-mediated excitability plausibly part of that failure, does changing that electrical threshold produce better plasticity rather than indiscriminate activation, and what measurable improvement in mood, motivation, cognition, sleep, and daily function would demonstrate that the network actually became healthier?”
That is the difference between:
- CALLING SOMETHING AN ANTIDEPRESSANT PEPTIDE
and:
- UNDERSTANDING NEURAL ELECTROPHYSIOLOGY.
STOP MEMORIZING PEPTIDES. START UNDERSTANDING THE SYSTEM.